D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
The densities of D1- and D2-type dopamine receptors were measured with [3H]SCH23390 and [3H]spiperone, in the caudate nucleus and putamen of a large series of patients with Parkinson's disease or progressive supranuclear palsy, in relation to markers of dopaminergic and cholinergic innervation of the striatum ([3H]dihydrotetrabenazine binding and choline acetyltransferase activity). Correlations were sought between these parameters and clinical characteristics of the patients (abnormal involuntary movements, dementia, confusional syndrome or treatment). In Parkinson's disease, the densities of both types of receptors were unchanged, whereas in PSP, the density of D2, but not D1-type dopamine receptors, was decreased in the caudate nucleus and the putamen. No correlations between the biochemical and clinical data were found.
Pierot
L
L
INSERM U. 289, Hôpital de la Salpêtrière, Paris, France.
Desnos
C
C
Blin
J
J
Raisman
R
R
Scherman
D
D
Javoy-Agid
F
F
Ruberg
M
M
Agid
Y
Y
D000262:Adenylyl Cyclases / Q000378:metabolism; D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000378:metabolism; D002421:Caudate Nucleus / Q000378:metabolism*; D018492:Dopamine Antagonists; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000378:metabolism*; D011699:Putamen / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism*; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012016:Reference Values; D013134:Spiperone / Q000378:metabolism; D013494:Supranuclear Palsy, Progressive / Q000378:metabolism*; D013747:Tetrabenazine / Q000031:analogs & derivatives / Q000378:metabolism
D001552:Benzazepines; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C032811:dihydrotetrabenazine; D013134:Spiperone; D000262:Adenylyl Cyclases; D013747:Tetrabenazine